Chronic cough, defined as a cough lasting more than eight weeks, is a common and often challenging condition encountered in clinical practice. Despite its prevalence, a significant number of patients remain undiagnosed or inadequately treated, leading to a substantial impact on quality of life and healthcare resources.
Understanding the pathophysiology of chronic cough is key to formulating a comprehensive diagnostic approach. The most common causes include upper airway cough syndrome (UACS), gastroesophageal reflux disease (GERD), and non-asthmatic eosinophilic bronchitis (NAEB). However, it is crucial to consider less common causes such as lung cancer, tuberculosis, and interstitial lung diseases, particularly in patients with risk factors or atypical presentations.
Diagnostic testing should be individualized based on the patient's clinical history and physical examination. High-resolution computed tomography (HRCT) can be useful in evaluating for structural lung diseases. Meanwhile, pulmonary function tests can help identify airflow obstruction or restriction. In patients with suspected GERD or UACS, pH monitoring or sinus imaging may be warranted.
Treatment should be targeted to the underlying cause. For instance, proton pump inhibitors may be effective for GERD-induced cough, while inhaled corticosteroids can be beneficial for NAEB. However, in cases where a specific cause is not identified, empirical treatment with cough suppressants, neuromodulators, or physical therapy may be considered.
Chronic cough remains a complex clinical problem requiring a comprehensive and individualized approach to diagnosis and treatment. Future research should focus on developing more effective diagnostic tools and treatment strategies, as well as understanding the pathophysiology of refractory chronic cough. With a systematic approach, clinicians can improve the management of this common, yet often challenging condition.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation